ROIVRoivant Sciences Ltd.
Price
+113%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, nothing alarming, growth fading, the market undecided.
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter.
In the company’s own words · 10-K filed May 20, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Roivant Sciences Ltd. (ROIV) reported revenue of $1.4M in Q1 2026 (quarter ended Jun 30, 2026), down 34% from the same quarter a year earlier. That came with net loss of $190M. For the full year FY2025, revenue was $8.3M (−72% year on year) and net income −$300M. The next results filing is expected around Nov 9, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 21, 2026Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)Regulation FD disclosure · press release
- Sep 8, 2026Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with.Regulation FD disclosure · press release
- Aug 28, 2026On August 28, 2026, Roivant Sciences Ltd. (the “Company”) posted a presentation regarding the approval by the U.S. Food and Drug Administration of LISRAYA™ (brepocitinib) for the treatment of adults with dermatomyositis on the “Events & Presentations” page of its investor relations website at investor.roivant.com.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.